Lysergic Acid Diethylamide

Phase 2Small molecule

EEleusis Therapeutics

Lysergic Acid Diethylamide is one of 23 small molecule programs targeting Cluster headache. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cluster HeadacheActive, not recruiting

Cluster HeadachePhase 2

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Cluster Headache

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Topamax

WWim Janssens

Approved

1 3

Emgality

Eli Lilly

Phase 3

3 4

Ajovy

Teva

Phase 3

3 5

Vyepti

Lundbeck

Phase 3

2 6

Xyrem

Jazz Pharmaceuticals

Phase 3

1 7

Rituxan

Roche

Phase 3

—8

Botox

RRevance Therapeutics, Inc.

Phase 3

3 9

Calan

VVal Adams

Phase 3

1 10

Sumatriptan Succinate

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

LSD5 trials

Effects of LSD on Neuroplasticity in Healthy Subjects

Completed·UUniversity of Fribourg·Phase 1·NCT05177419·45 enrolled

Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT05175430·24 enrolled

Effect of Ketanserin After LSD Administration

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT04558294·24 enrolled

Show 2 more trials

Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT04516902·24 enrolled

A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers

Completed·EEleusis Therapeutics·Phase 1·NCT05674669·32 enrolled

Cluster headache1 trial

Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT03781128·30 enrolled

Mood1 trial

Mood Effects of Serotonin Agonists

Completed·UUniversity of Chicago·Phase 1·NCT03790358·80 enrolled

Biomarker1 trial

Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy

Completed·TTatiana Aboulafia Brakha··NCT06557239·10 enrolled

Double-blind1 trial

A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years

Completed·EEleusis Therapeutics·Phase 1·NCT04421105·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Lysergic Acid Diethylamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lysergic Acid Diethylamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lysergic Acid Diethylamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eleusis Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEleusis Therapeutics

Lysergic Acid Diethylamide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

LSD5 trials

Cluster headache1 trial

Mood1 trial

Biomarker1 trial

Double-blind1 trial

References

Drug Info

Quick Facts

Related News